Table 4.
On-treatment HDL measures in relation to incident CVD events, by treatment group
| Tertile One | Tertile Two | Tertile Three | P-trend | HR per 1-SD increase | PLRT# | |
|---|---|---|---|---|---|---|
| Placebo (No. events/N: 144/5114) | ||||||
|
| ||||||
| HDL cholesterol, mg/dL | ≤46 | 47–58 | >58 | |||
|
| ||||||
| Incidence (95% CI)* | 1.78 (1.43–2.20) | 0.84 (0.59–1.20) | 0.90 (0.63–1.28) | |||
| Adjusted HR (95% CI)** | 1.00 | 0.47 (0.30–0.73) | 0.50 (0.31–0.81) | 0.003 | 0.79 (0.63–0.98) | 0.03 |
|
| ||||||
| Apolipoprotein A-I, mg/dL | ≤ 152 | 153–178 | >178 | |||
|
| ||||||
| Incidence (95% CI) | 1.73 (1.37–2.18) | 1.10 (0.82–1.48) | 0.82 (0.57–1.18) | |||
| Adjusted HR (95% CI) | 1.00 | 0.67 (0.46–0.99) | 0.51 (0.32–0.82) | 0.004 | 0.75 (0.62–0.92) | 0.004 |
|
| ||||||
| HDL size | ≤8.8 | 8.9–9.3 | >9.3 | |||
|
| ||||||
| Incidence (95% CI) | 1.17 (0.91–1.50) | 1.44 (1.09–1.90) | 1.11 (0.79–1.57) | |||
| Adjusted HR (95% CI) | 1.00 | 1.42 (0.95–2.11) | 1.06 (0.65–1.73) | 0.62 | 0.94 (0.77–1.15) | 0.54 |
|
| ||||||
| HDL particles | ≤30.0 | 30.1–35.1 | >35.1 | |||
|
| ||||||
| Incidence (95% CI) | 1.48 (1.17–1.87) | 1.29 (0.98–1.71) | 0.81 (0.55–1.19) | |||
| Adjusted HR (95% CI) | 1.00 | 1.00 (0.69–1.45) | 0.68 (0.43–1.08) | 0.13 | 0.81 (0.67–0.97) | 0.02 |
|
| ||||||
| Rosuvastatin (No. events/N: 82/4932) | ||||||
|
| ||||||
| HDL cholesterol, mg/dL | ≤46 | 47–58 | >58 | |||
|
| ||||||
| Incidence (95% CI) | 0.94 (0.68–1.31) | 0.67 (0.44–1.01) | 0.61 (0.41–0.90) | |||
| Adjusted HR (95% CI) | 1.00 | 0.71 (0.40–1.27) | 0.71 (0.38–1.30) | 0.28 | 0.82 (0.63–1.08) | 0.16 |
|
| ||||||
| Apolipoprotein A-I, mg/dL | ≤152 | 153–178 | >178 | |||
|
| ||||||
| Incidence (95% CI) | 0.85 (0.59–1.22) | 0.82 (0.57–1.18) | 0.54 (0.36–0.82) | |||
| Adjusted HR (95% CI) | 1.00 | 0.93 (0.55–1.59) | 0.72 (0.39–1.32) | 0.29 | 0.86 (0.67–1.10) | 0.22 |
|
| ||||||
| HDL size | ≤8.8 | 8.9–9.3 | >9.3 | |||
|
| ||||||
| Incidence (95% CI) | 0.68 (0.48–0.96) | 0.69 (0.47–1.01) | 0.69 (0.47–1.02) | |||
| Adjusted HR (95% CI) | 1.00 | 1.04 (0.60–1.83) | 1.19 (0.64–2.23) | 0.58 | 1.07 (0.82–1.39) | 0.64 |
|
| ||||||
| HDL particles | ≤30.0 | 30.1–35.1 | >35.1 | |||
|
| ||||||
| Incidence (95% CI) | 1.21 (0.88–1.68) | 0.71 (0.49–1.05) | 0.45 (0.29–0.70) | |||
| Adjusted HR (95% CI) | 1.00 | 0.63 (0.38–1.06) | 0.44 (0.25–0.79) | 0.005 | 0.73 (0.57–0.93) | 0.01 |
*
Incidence per 100 person-years
**
Cox proportional hazard ratios were adjusted for age, sex, race, smoking, systolic blood pressure, body-mass index, fasting glucose, LDL cholesterol, triglycerides, and family history of premature CHD. Standard deviations (SDs) were 15.3 mg/dL for HDL-C, 30.2 mg/dL for apolipoprotein A-I, 0.52 nm for HDL size, and 6.32 μmol/L for HDL-P.
#
Likelihood ratio chi2 comparing a model that adds either HDL-C, HDL size, or HDL-P to the basic risk factors of age, sex, race, smoking, systolic blood pressure, body-mass index, fasting glucose, LDL cholesterol, triglycerides, and family history of premature CHD.